Healthcare - Biotechnology - NASDAQ - US
$ 0.043
3.61 %
$ 2.34 M
Market Cap
-0.09
P/E
CASH FLOW STATEMENT
-44.8 M
OPERATING CASH FLOW
27.3 M
INVESTING CASH FLOW
31.5 M
FINANCING CASH FLOW
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis
Galera Therapeutics, Inc.
| Net Income | -59.1 M |
| Depreciation & Amortization | 259 K |
| Capital Expenditures | -59 K |
| Stock-Based Compensation | 5.56 M |
| Change in Working Capital | -2.93 M |
| Others | 10.6 M |
| Free Cash Flow | -44.9 M |
Cash Flow
Millions
| Dec-2023 | Dec-2022 | Dec-2021 | Dec-2020 | Dec-2019 | Dec-2018 | Dec-2017 | |
|---|---|---|---|---|---|---|---|
| OPERATING CASH FLOW | |||||||
| Net Income | (59.1) | (62.2) | (80.5) | (74.2) | (51.9) | (23.7) | (23.5) |
| Depreciation & Amortization | 0.3 | 0.1 | 0.8 | 0.4 | 0.3 | 0.1 | 84 K |
| Deferred Income Tax | 0 | 70 K | 0 | 16 K | 0.2 | 0 | 0 |
| Stock Based Compensation | 5.6 | 7.2 | 7.2 | 5.5 | 2.4 | 0.9 | 0.7 |
| Other Operating Activities | 11.3 | 11.6 | 7.2 | 4.9 | 3.0 | 0.2 | 1.6 |
| Change in Working Capital | (2.9) | 17 K | (2.6) | 3.9 | (0.7) | 0.3 | (0.7) |
| Cash From Operations | (44.8) | (43.4) | (68.0) | (59.5) | (46.7) | (22.2) | (23.4) |
| INVESTING CASH FLOW | |||||||
| Capital Expenditures | 59 K | 25 K | (0.3) | (0.5) | (0.6) | (0.3) | (0.3) |
| Other Items | 27.4 | 24.0 | 5.5 | 37.0 | (27.2) | (58.7) | 23.8 |
| Cash From Investing Activities | 27.3 | 24.0 | 5.2 | 36.5 | (27.8) | (59.0) | 23.5 |
| FINANCING CASH FLOW | |||||||
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Debt Repaid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2 | 81 K | 58.8 | 20.5 | 20.0 | 89.8 | 0 |
| Cash From Financing Activities | 31.5 | 3.9 | 66.7 | 20.5 | 78.0 | 89.8 | 0 |
| CHANGE IN CASH | |||||||
| Net Change In Cash | 13.9 | (15.5) | 4.0 | (2.5) | 3.5 | 8.6 | 0.1 |
| FREE CASH FLOW | |||||||
| Free Cash Flow | (44.9) | (43.5) | (68.2) | (60.0) | (47.3) | (22.5) | (23.7) |